Insider Selling: Castle Biosciences, Inc. (NASDAQ:CSTL) Director Sells $196,310.40 in Stock

Castle Biosciences, Inc. (NASDAQ:CSTL – Get Free Report) Director Daniel Bradbury sold 9,152 shares of Castle Biosciences stock in a transaction that occurred on Thursday, April 4th. The stock was sold at an average price of $21.45, for a total value of $196,310.40. Following the transaction, the director now owns 22,782 shares in the company, […]

Related Keywords

Canada ,Castle Biosciences ,Daniel Bradbury ,Lazard Asset Management ,Castle Biosciences Inc ,Scotiabank ,Dell Group ,Royal Bank ,Securities Exchange Commission ,Castle Biosciences Company Profile ,Tower Research Capital ,Bluepath Capital Management ,Nasdaq ,Keycorp ,Get Free Report ,Director Daniel Bradbury ,Exchange Commission ,Biosciences Stock Down ,Asset Management ,Path Capital Management ,Research Capital ,Mypath Melanoma ,Castle Biosciences Daily ,Nasdaq Cstl ,Cstl ,Medical ,Insider Trading ,Nsider Trades ,Stocks ,